UBS AM
IRWD icon

UBS AM’s Ironwood Pharmaceuticals IRWD Stock Holding History

UBS AM’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,643
Closed -$15.5K – 2441
2025
Q2 		$15.5K Sell
21,643
-265,347
-92% -$208K ﹤0.01% 2614
2025
Q1 		$422K Hold
286,990
– – ﹤0.01% 2522
2024
Q4 		$1.27M Buy
286,990
+17,265
+6% +$70K ﹤0.01% 2265
2024
Q3 		$1.11M Sell
269,725
-38,965
-13% -$209K ﹤0.01% 2347
2024
Q2 		$2.01M Buy
308,690
+158,175
+105% +$1.12M ﹤0.01% 1997
2024
Q1 		$1.31M Sell
150,515
-6,487
-4% -$78.7K ﹤0.01% 1882
2023
Q4 		$1.8M Buy
157,002
+23,086
+17% +$228K ﹤0.01% 1743
2023
Q3 		$1.29M Sell
133,916
-22,455
-14% -$220K ﹤0.01% 1822
2023
Q2 		$1.65M Hold
156,371
– – ﹤0.01% 1763
2023
Q1 		$1.65M Sell
156,371
-8,983
-5% -$101K ﹤0.01% 1763
2022
Q4 		$2.05M Buy
165,354
+37,205
+29% +$422K ﹤0.01% 1510
2022
Q3 		$1.33M Buy
128,149
+11,362
+10% +$129K ﹤0.01% 1803
2022
Q2 		$1.35M Sell
116,787
-123,285
-51% -$1.45M ﹤0.01% 1813
2022
Q1 		$3.02M Hold
240,072
– – ﹤0.01% 1583
2021
Q4 		$2.8M Sell
240,072
-989,038
-80% -$12.1M ﹤0.01% 1714
2021
Q3 		$16.1M Sell
1,229,110
-676,165
-35% -$8.74M 0.01% 929
2021
Q2 		$24.5M Buy
1,905,275
+49,189
+3% +$563K 0.01% 840
2021
Q1 		$20.8M Sell
1,856,086
-588,177
-24% -$6.21M 0.01% 854
2020
Q4 		$27.8M Sell
2,444,263
-1,009,979
-29% -$11.1M 0.01% 758
2020
Q3 		$31.1M Sell
3,454,242
-2,986,625
-46% -$29.7M 0.02% 647
2020
Q2 		$66.5M Sell
6,440,867
-1,415,024
-18% -$14.5M 0.04% 414
2020
Q1 		$79.3M Sell
7,855,891
-888,342
-10% -$10.4M 0.06% 331
2019
Q4 		$116M Sell
8,744,233
-1,913,331
-18% -$21.1M 0.07% 291
2019
Q3 		$91.5M Buy
10,657,564
+458,799
+4% +$4.46M 0.06% 335
2019
Q2 		$112M Buy
10,198,765
+1,692,670
+20% +$19M 0.08% 269
2019
Q1 		$96.4M Sell
8,506,095
-296,860
-3% -$3.32M 0.07% 289
2018
Q4 		$76.4M Buy
8,802,955
+1,413,768
+19% +$16.2M 0.07% 318
2018
Q3 		$114M Sell
7,389,187
-325,402
-4% -$5.14M 0.08% 259
2018
Q2 		$124M Buy
7,714,589
+817,135
+12% +$12.1M 0.09% 245
2018
Q1 		$89.1M Sell
6,897,454
-694,421
-9% -$8.65M 0.07% 316
2017
Q4 		$95.3M Sell
7,591,875
-58,333
-0.8% -$762K 0.08% 276
2017
Q3 		$101M Buy
7,650,208
+3,351,486
+78% +$46.1M 0.09% 246
2017
Q2 		$68M Buy
4,298,722
+2,695,463
+168% +$39.2M 0.07% 321
2017
Q1 		$22.9M Buy
1,603,259
+1,542,466
+2,537% +$21.1M 0.02% 673
2016
Q4 		$779K Sell
60,793
-29,694
-33% -$375K ﹤0.01% 1653
2016
Q3 		$1.2M Buy
90,487
+1,671
+2% +$19.5K ﹤0.01% 1604
2016
Q2 		$973K Buy
88,816
+2,201
+3% +$21.5K ﹤0.01% 1665
2016
Q1 		$794K Sell
86,615
-29,134
-25% -$240K ﹤0.01% 1729
2015
Q4 		$1.12M Buy
115,749
+3,831
+3% +$37K ﹤0.01% 1697
2015
Q3 		$977K Buy
111,918
+37,058
+50% +$346K ﹤0.01% 1731
2015
Q2 		$756K Buy
74,860
+14,686
+24% +$171K ﹤0.01% 1823
2015
Q1 		$806K Buy
60,174
+8,239
+16% +$108K ﹤0.01% 1729
2014
Q4 		$666K Sell
51,935
-239
-0.5% -$2.73K ﹤0.01% 1782
2014
Q3 		$566K Buy
52,174
+1,074
+2% +$12.3K ﹤0.01% 1806
2014
Q2 		$656K Buy
51,100
+2,747
+6% +$29.9K ﹤0.01% 1758
2014
Q1 		$499K Buy
48,353
+4,537
+10% +$51K ﹤0.01% 1898
2013
Q4 		$426K Buy
43,816
+13,850
+46% +$124K ﹤0.01% 1897
2013
Q3 		$297K Hold
29,966
– – ﹤0.01% 2086
2013
Q2 		$250K Buy
+29,966
New +$363K ﹤0.01% 2124

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS AM's IRWD Position: Q3 2025 in Review

UBS AM sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2025, closing a stake of 21,643 shares — an estimated $15.5K sold.

UBS AM first reported a position in IRWD in Q2 2013 and held it in 49 quarters. The position peaked at $124M in Q2 2018. 166 funds tracked by Wall St. Rank hold IRWD as of Q3 2025.

  • UBS AM reported no remaining Ironwood Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS AM sold 21,643 Ironwood Pharmaceuticals shares in Q3 2025, an estimated $15.5K.
  • UBS AM first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 49 quarters.
  • UBS AM's Ironwood Pharmaceuticals position peaked at $124M in Q2 2018.
  • 166 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2025.

Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.